congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
T-DXd, Valemetostat
ESMO GI 2024 | June 26 – 29, 2024
Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated, advanced, or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma